Tarsus Medical Affairs

Our Medical Affairs team is a peer-based resource for healthcare providers. We are committed to advancing science and medicine through awareness, education, and research.

Our Senior Medical Ambassadors (SMAs) are field-based scientific and medical peers, empowered to serve our healthcare providers.

SMA Access — find a scientifically trained Tarsus field medical professional near you.

MEDICAL AFFAIRS TEAM

Find your SMA using the map


SOUTHWEST

MEDICAL AFFAIRS TEAM

Find your SMA using the map


NORTH CENTRAL

MEDICAL AFFAIRS TEAM

Find your SMA using the map


SOUTHEAST

Research Grants

The Tarsus research grant program is committed to supporting studies sponsored by qualified third-party investigators or institutions that advance medical and scientific knowledge to healthcare professionals and promotes excellence in patient care. Studies are generally exploratory in nature with smaller sample sizes, or case studies, and offer valuable clinical insights.

Qualified investigators can submit an unsolicited research concept for a research grant aligned with the following strategic areas of interest:

  • Demodex blepharitis
  • Meibomian gland disease (MGD)

To be considered for review, the proposal must include a short abstract with study objective(s) and outcome measures.

For more information about our research grant program, please reach out to your Senior Medical Ambassador.

Investigator-Initiated Trials

As a part of our commitment to advancing science and medicine, Tarsus believes in supporting independent and ethical clinical research, designed and conducted by qualified third-party investigators.

Investigator-initiated trials (IITs) represent investigator-sponsored, scientifically sound studies with capabilities to expand our understanding of our products, improve patient care, and spark new ideas for further disease-related research.

Qualified investigators can submit an unsolicited IIT concept for an investigator-initiated trial aligned with the following strategic areas of interest:

  • Demodex blepharitis
  • Meibomian gland disease (MGD)

To be considered for review, the proposal must include study objective(s), hypotheses, endpoints, and a short abstract.

For more information about our investigator-initiated trials, please reach out to your Senior Medical Ambassador.

Independent medical education grants and medical sponsorships

Independent Medical Education Grants

  • Tarsus recognizes the importance of independent medical education and provides financial support for accredited and nonaccredited professional education for US healthcare providers. Please ensure that your organization can be classified as one of the following: academic medical center/university, professional society/association, medical education provider, or hospital/clinic.
  • It is important to note that Tarsus cannot provide any advice or guidance on any aspect of the program, including but not limited to the following:
    • Program content
    • Speaker/faculty selection
    • Venue selection
    • Methods that ensure educational effectiveness
    • Methods that ensure the meeting of compliance and regulatory requirements
    • Submission for accredited continuing education (CE) programs
  • Tarsus is currently considering support for independent medical education programs that focus on Demodex blepharitis.

Medical Sponsorships

  • Tarsus is dedicated to furthering the goals of independent professional educational and patient-focused organizations. Medical Sponsorships can be directly provided only to Independent Organizations and not individual healthcare providers or group practices.

Contact the Medical Affairs team

Tarsus is committed to providing high-quality and consistent medical information. We recognize the importance of having access to trusted, accurate, and balanced clinical and scientific information about our products.

Use this form to contact the Medical Affairs team with any questions you may have.

Publications

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

August 2024

Ocular and systemic pharmacokinetics of lotilaner ophthalmic solution, 0.25%, following a single dose or repeated doses in dutch-belted rabbits

Abstract

Purpose: To evaluate the ocular and systemic pharmacokinetics of lotilaner ophthalmic solution, 0.25%, following bilateral topical ocular administration of single and repeated doses in rabbits.

HEALTHCARE

July 2024

Lotilaner ophthalmic solution, 0.25%, for the treatment of Demodex blepharitis

Abstract

Purpose: Demodex blepharitis, a chronic lid margin disease, is caused by an infestation of Demodex mites, the most common ectoparasites in human skin and eyelids.

Optometry and Vision Science

March 2024

The impact of Demodex blepharitis on patient symptoms and daily life

Abstract

Purpose: This study aimed to evaluate the effect of Demodex blepharitis on patients' daily activities and well-being.

Cornea

February 2024

Long-term outcomes of 6-week treatment of lotilaner ophthalmic solution, 0.25%, for Demodex blepharitis: a noninterventional extension study

Abstract

Purpose: The aim of this study was to evaluate the long-term outcomes of lotilaner ophthalmic solution, 0.25%, in the treatment of Demodex blepharitis.

Drugs

October 2023

Lotilaner ophthalmic solution 0.25%: first approval

Abstract

Purpose: This article summarizes the milestones in the development of lotilaner ophthalmic solution 0.25% leading to this first approval for the treatment of Demodex blepharitis in the USA.

Ophthalmology

October 2023

Lotilaner ophthalmic solution 0.25% for Demodex blepharitis: randomized, vehicle-controlled, multicenter, phase 3 Trial (Saturn-2)

Abstract

Purpose: To evaluate the safety and efficacy of lotilaner ophthalmic solution 0.25% compared with vehicle for the treatment of Demodex blepharitis.

Eye & Contact Lens: Science and Clinical Practice

August 2023

Demodex blepharitis: a comprehensive review of the disease, current management, and emerging therapies

Abstract

Purpose: This article reviews what is known about the mechanisms and impact of Demodex blepharitis, risk factors, signs and symptoms, diagnostic techniques, current management options, and emerging treatments.

Cornea

April 2023

Lotilaner ophthalmic solution, 0.25%, for the treatment of Demodex blepharitis: results of a prospective, randomized, vehicle-controlled, double-masked, pivotal trial (Saturn-1)

Abstract

Purpose: The purpose of this study was to evaluate the safety and efficacy of lotilaner ophthalmic solution, 0.25%, compared with vehicle for the treatment of Demodex blepharitis.

Eye (Lond)

March 2023

Clinical diagnosis and management of Demodex blepharitis: the Demodex Expert Panel on Treatment and Eyelid Health (DEPTH)

Abstract

Purpose: Twelve ocular surface disease experts convened to achieve consensus about Demodex blepharitis (DB) using a modified Delphi panel process.

CLINICAL OPHTHALMOLOGY

February 2023

Delphi panel consensus regarding current clinical practice management options for Demodex blepharitis

Abstract

Purpose: To obtain consensus on Demodex blepharitis (DB) treatment using a modified Delphi panel process.

Clinical Ophthalmology

September 2022

Psychosocial impact of Demodex blepharitis

Abstract

Purpose: To evaluate the impact of Demodex blepharitis on patients’ daily activities and quality of life.

Ocular Immunology and Inflammation

August 2022

Treatment of Demodex blepharitis: a prospective, randomized, controlled, double-masked clinical trial comparing topical lotilaner ophthalmic solution, 0.25% eyedrops to vehicle

Abstract

Purpose: To evaluate the efficacy and safety of lotilaner ophthalmic solution, 0.25% eyedrops compared to vehicle for the treatment of Demodex blepharitis.

Contact Lens & Anterior Eye

August 2022

Safety and efficacy of lotilaner ophthalmic solution, 0.25% for the treatment of blepharitis due to Demodex infestation: a randomized, controlled, double-masked clinical trial

Abstract

Purpose: To evaluate the safety and efficacy of lotilaner ophthalmic solution, 0.25% for the treatment of blepharitis due to Demodex infestation compared to vehicle control.

Clinical Ophthalmology

April 2022

The prevalence of Demodex blepharitis in US eye care clinic patients as determined by collarettes: a pathognomonic sign

Abstract

Purpose: To evaluate the prevalence of Demodex blepharitis by its pathognomonic sign, collarettes, in patients presenting for any reason to eye care clinics in the United States.

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

October 2021

Collarette elimination and Demodex mite eradication with topical lotilaner ophthalmic solution, 0.25%

Abstract

Purpose: To evaluate the efficacy of topical lotilaner ophthalmic solution, 0.25%, in patients with Demodex blepharitis.

Journal of Ophthalmology

September 2021

Safety and efficacy of topical lotilaner ophthalmic solution 0.25% for the treatment of Demodex blepharitis: a pilot study

Abstract

Purpose: To evaluate safety and efficacy of topical lotilaner ophthalmic solution, 0.25% for the treatment of Demodex blepharitis.